Overview

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2028-10-01

Target enrollment:

Participant gender:

Summary

This project is a prospective, open-label, randomized controlled clinical study. It plans to enroll 60 patients with unresectable HCC and no distant metastasis, randomly assigned to the experimental group and the control group, with 30 cases in each group. The experimental group was treated with radiotherapy combined with immunotherapy and Bevacizumab, while the control group was treated with immunotherapy and Bevacizumab. The efficacy of the patients and the conversion rate to surgery were evaluated.

Phase:

PHASE2

Details

Lead Sponsor:

Hebei Medical University Fourth Hospital

Treatments:

Bevacizumab
Radiotherapy
sintilimab